Redhill Boipharma Share Price - RDHL

1.14 (23.84%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Redhill Boipharma Ltd RDHL NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
1.14 23.84% 5.895 5.3403 6.30 5.90 4.76 12:08:26
Bid Price Ask Price Spread Spread % News
5.90 5.91 0.01 0.17% 2 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
5,515 1,072,126  5.79  6,212,645 264,672
Last Trade Time Type Quantity Stock Price Currency
12:08:22 100  5.895 USD

Redhill Boipharma Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
 202.80M 35.27M  -38.82M -1.30 - 35.27M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Redhill Boipharma

Loading Messages....

Latest RDHL Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

RDHL Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Redhill Biopharma Ltd is an Israel-based specialty biopharmaceutical company. The company focuses on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. Its operating segment includes Commercial Operations and Research and Development. The company generates maximum revenue from the Commercial Operations segment. Its Commercial products include Aemcolo; Talicia and EnteraGam. The clinical-stage pipeline includes RHB-104, oral combination therapy for the treatment of Crohn's disease, RHB-204, for pulmonary nontuberculous mycobacteria (NTM) infections, RHB-102 (Bekinda), a once-daily oral pill formulation of ondansetron, ABC294640 (Yeliva), RHB-106, and RHB-107.

Your Recent History
Redhill Bo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.